Sunday, August 9, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Banking & Insurance

Allianz Pushes Into Energy Infrastructure as Buybacks Lift Stock to 52-Week High; Berenberg Sees 60% More Room

SiterGedge by SiterGedge
July 7, 2026
in Banking & Insurance, DAX, Dividends
0
Allianz Stock
0
SHARES
21
VIEWS
Share on FacebookShare on Twitter

Allianz shares edged within a whisker of a new 12-month high on Tuesday, touching €423.00 as the insurance heavyweight continued to reap the rewards of an aggressive share buyback programme and solid operating momentum. The stock now sits just 0.21% below the 52-week peak of €423.90, having gained 13.19% over the past 30 days and 8.82% since the start of the year. At current levels, the price stands more than 26% above the 12-month low of €334.90.

The buyback remains the central engine of the rally. In June alone, Allianz snapped up roughly one million of its own shares at a total cost of around €386 million. As of early July, the company had repurchased nearly 4 million shares since the programme began on 13 March 2026, with a single tranche of 294,500 shares executed in the first days of July. This steady demand is effectively cushioning any downside moves and compressing the free float, while lifting earnings per share — currently €30.97, translating into a price-to-earnings ratio of roughly 13.65. With a market capitalisation of €160.84 billion and a 7.44% weighting in the DAX, Allianz ranks as the index’s fourth-largest constituent.

Berenberg analyst Michael Huttner, however, argues that the market has barely scratched the surface. He reaffirmed a target of €684 per share, implying potential upside of 60% from current levels. His thesis rests on the belief that investors are underappreciating the financial strength of European composite insurers. The sector is trading on a 2028 price-to-earnings multiple of 12, but Berenberg contends a multiple of 20 is justified over the longer term.

Operationally, Allianz provided plenty of ammunition for that bullish case. The first quarter delivered an operating profit of roughly €4.5 billion, up almost 7% year on year. The property and casualty division posted a double-digit earnings jump, while the solvency II ratio remained a rock-solid 221%. In an environment defined by global financial anxiety, the group has positioned itself as a stability anchor.

Should investors sell immediately? Or is it worth buying Allianz?

Meanwhile, the asset management arm Allianz Global Investors is making a strategic bet on Europe’s energy transition. The subsidiary sees massive capital demand from the expansion of power grids and battery storage, with a particular tailwind from artificial intelligence and data-centre growth. Allianz GI expects European data-centre capacity to double from around 20 gigawatts to 40 gigawatts over the next five years. The firm is already investing in large battery-storage projects in Germany and holds a stake in transmission grid operator Amprion.

Yet the record share price does not shield Allianz from regulatory headwinds. On Tuesday, non-governmental organisations called for an additional capital buffer of more than 20% for insurers, aimed at better covering climate risks on their balance sheets. In Germany, the long-running debate over mandatory natural-hazard insurance remains unresolved. Ergo CEO Olaf Bläser warned that without stricter building rules in flood zones and complementary prevention measures, compulsory coverage alone would achieve little.

For all the fundamental strength, the chart paints a more cautious near-term picture. The stock is trading 8.42% above its 50-day moving average of €390.14 and 12.63% above the 200-day moving average. The relative strength index on a 14-day basis stands at 80.0 — firmly in overbought territory. That suggests elevated vulnerability to short-term swings, even if the 30-day volatility reading of 13.64% remains moderate.

With a year-to-date gain of 21% already in the bag, Allianz is among the strongest performers in the DAX. The next catalyst will be the quarterly results, where the board must demonstrate it can manage normalising premium cycles and global risks effectively. Should the operational momentum hold, Berenberg’s ambitious scenario will gain considerable credibility — but the immediate hurdle posed by an overbought technical profile is one the market will have to clear first.

Ad

Allianz Stock: Buy or Sell?! New Allianz Analysis from August 8 delivers the answer:

The latest Allianz figures speak for themselves: Urgent action needed for Allianz investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 8.

Allianz: Buy or sell? Read more here...

Tags: Allianz
SiterGedge

SiterGedge

Related Posts

Petrobras Stock
Chemicals

Petrobras Delivers Record-Breaking Quarter, But Investors Keep Their Distance

August 8, 2026
Münchener Rück Stock
Banking & Insurance

Munich Re’s €2.2bn Quarter Raises the Stakes on a Quiet Hurricane Season

August 7, 2026
Deutsche Telekom Stock
DAX

Telekom’s €5bn Buyback Pledge Shifts the Spotlight From Bonn to T-Mobile US

August 7, 2026
Next Post
Nel ASA Stock

Nel ASA Shifts the Narrative from Climate to Security as a Cost Breakthrough Fails to Move the Needle

Commerzbank Stock

Commerzbank’s 1% Acceptance: How UniCredit Built a 40% Stake Without Most Shareholders’ Backing

FALLBACK Stock

From World Records to Spinal Implants: The New Arsenal Against Back Pain

Recommended

Biotechnology Stock Bull Market

Analyst Reiterates Buy Rating and 12 Price Target for Shattuck Labs Citing Promising Potential in Biotech Sector

2 years ago
Sangamo Therapeutics Stock

A Regulatory Milestone Sparks Renewed Interest in Sangamo Therapeutics

7 months ago
Diginex Stock

Leadership Shift at Diginex as ESG Software Founder Takes Helm

6 months ago
Novo Nordisk Stock

Novo Nordisk’s Bold Gambit: Price Cuts and Restructuring Amid Market Pressure

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Petrobras Delivers Record-Breaking Quarter, But Investors Keep Their Distance

Milan Fertility Clinic Suspended After Embryo Mix-Up Sparks Safety Reforms Across Europe

AppLovin’s $40 Billion Wake-Up Call: When a 53% Growth Rate Isn’t Enough

Atlassian’s €128.80 Spike: A Profitability Inflection Point Arrives Just as Growth Slows

Amazon’s Three-Trillion-Dollar Moment: A Founder’s Exit, a $220 Billion Wager, and the Fine Print Behind the Record Numbers

The AI Payoff Shifts: Airbnb, SpaceX, and Crypto Show Their Hand

Trending

Novo Nordisk Stock
European Markets

Novo Nordisk’s Oral Push Marks a Sales Milestone as Trial Setbacks and Rival Pressure Keep the Spotlight on the Pipeline

by SiterGedge
August 8, 2026
0

Novo Nordisk is getting one piece of good news that is easy to count: Wegovy has now...

Nvidia Stock

Nvidia’s Latest Surge Is About More Than a Single Order

August 8, 2026
Plug Power Stock

Plug Power’s Balancing Act: Property Sales Fund the Present While Australia’s Hydrogen Hub Points to the Future

August 8, 2026
Petrobras Stock

Petrobras Delivers Record-Breaking Quarter, But Investors Keep Their Distance

August 8, 2026
FALLBACK Stock

Milan Fertility Clinic Suspended After Embryo Mix-Up Sparks Safety Reforms Across Europe

August 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Novo Nordisk’s Oral Push Marks a Sales Milestone as Trial Setbacks and Rival Pressure Keep the Spotlight on the Pipeline
  • Nvidia’s Latest Surge Is About More Than a Single Order
  • Plug Power’s Balancing Act: Property Sales Fund the Present While Australia’s Hydrogen Hub Points to the Future

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com